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Abstract
The LeishVet group has formed recommendations designed primarily to help the veterinary clinician in the
management of canine leishmaniosis. The complexity of this zoonotic infection and the wide range of its clinical
manifestations, from inapparent infection to severe disease, make the management of canine leishmaniosis
challenging. The recommendations were constructed by combining a comprehensive review of evidence-based
studies, extensive clinical experience and critical consensus opinion discussions. The guidelines presented here in a
short version with graphical topic displays suggest standardized and rational approaches to the diagnosis,
treatment, follow-up, control and prevention of canine leishmaniosis. A staging system that divides the disease into
four stages is aimed at assisting the clinician in determining the appropriate therapy, forecasting prognosis, and
implementing follow-up steps required for the management of the leishmaniosis patient.
Background
Canine leishmaniosis (CanL) due to Leishmania infan-
tum is a major global zoonosis potentially fatal to
humans and dogs, which comprise the main reservoir of
infection to humans [1]. CanL is endemic in more than
70 countries in the world. It is present in regions of
southern Europe, Africa, Asia, South and Central Amer-
ica [2] and has been reported also in the United States
of America (USA) [3]. It is also an important concern
in non-endemic countries where imported sick or
infected dogs constitute a veterinary and public health
problem [4].
CanL is manifested by a broad spectrum of clinical
signs and degrees of severity, and there is insufficient
scientific agreement on the management of this disease
[2]. LeishVet is a group of veterinary scientists from aca-
demic institutes in Europe and the Mediterranean basin
with a main clinical and scientific interest in CanL. The
main goal of LeishVet is to develop consensus recom-
mendations that would represent the most current
understanding of L. infantum infection in dogs based on
recent evidence-based literature and clinical experience
[2]. The objective of these guidelines is to help
practitioners in the clinical management of CanL with
emphasis on diagnosis, clinical staging, treatment, clini-
cal monitoring, prognosis and prevention.
Life cycle and transmission
Leishmania completes its life cycle in two hosts, a phle-
botomine sand fly vector, which transmits the flagellated
infective promastigote form, and a mammal, where the
intracellular amastigote form develops and replicates
(Figure 1). Sand flies are the only arthropods that are
adapted for biological transmission of Leishmania. The
relatively low proportion of sand flies harbouring L.
infantum (0.5 - 3%) is sufficient for maintaining the
infection in endemic areas. Non-sand fly modes of
transmission have also been described but their role in
the natural history and epidemiology of leishmaniosis
remains unclear (Figure 1). Proven modes of non-sand
fly transmission include infection through transfused
blood products [5] from blood donors which are carriers
of infection [6,7], vertical [8-10] and venereal transmis-
sion [11]. The adequate selection of canine blood donors
is of great importance for the prevention of L. infantum
infection and recommendations on donor selection are
graphically summarized in Figure 2. Suspected yet
unproven modes of transmission include: 1) direct dog-
to-dog transmission through bites or wounds, which
could explain the presence of autochthonous CanL
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1. Classical life cycle of Leishmania infantum
1a. Promastigote
1b. Amastigote
1c. Parasite dissemination to organs in macrophages
2. Other unusual modes of transmission
2a. Vertical
2b. Blood transfusion
2c. Venereal transmission
Other (unproven): Dog to dog (bites, wounds)
1b
1a
1c 2
2a
2c
2b
1
Figure 1 The life cycle of L. infantum with indication of proven and unproven non-sandfly routes of transmission to dogs.
Figure 2 Algorithm describing the selection of blood donors and exclusion of infected dogs. Any dog infected will be excluded.
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clinical cases [12] in non-endemic areas in the absence
of apparent vectors, as described in foxhounds in the
USA [13] or in breeding kennels in Europe [14], and 2)
transmission by other hematophagous arthropods such
as ticks and fleas [15-21] (Figure 1).
Distribution and epidemiology
Socioeconomic and possible climate factors have led to
changes in the distribution of CanL in Europe (Figure 3).
Leishmania infantum infection has spread northward
reaching the foothills of the Alps in northern Italy [22]
and of the Pyrenees in France [14] and northern Spain
[23]. The large numbers of dogs travelling to southern
Europe or imported as companion animals from areas
where CanL is endemic have increased the number of
clinical cases reported in non endemic countries such as
the United Kingdom [12] and Germany [24].
Leishmania infantum frequently follows an insidious and
chronic pattern of infection [25]. Therefore, CanL is a dis-
ease in which infection does not equal clinical illness result-
ing in a high prevalence of subclinical infection [2,26].
A broad range of immune responses and clinical
manifestations have been described in CanL (Figure 4).
Infection in dogs may be subclinical or manifested as
a self-limiting disease, or a severe, and sometimes,
fatal illness [27]. Subclinical infection is not necessa-
rily permanent and factors such as immunosuppres-
sion or concomitant diseases could break the
equilibrium and lead to the progression of clinical
disease in dogs [2,27] as observed in humans coin-
fected with human immunodeficiency virus and Leish-
mania [28].
Several predisposing factors for the development of
disease have been described including breed, age and
genetic background. Some dog breeds such as the
Boxer, Cocker Spaniel, Rottweiler and German Shepherd
seem to be more susceptible to the development of dis-
ease [29,30], while others such as the Ibizian Hound
rarely develop clinical signs of CanL [31]. The Slc11c1
(Solute carrier family 11 member a1) gene, formerly
named N-RAMPI, and certain alleles of the MHC II
genes have been associated with susceptibility to CanL
[32,33]. Age seems to be an important factor. The distri-
bution of the disease is bimodal, with the highest preva-
lence reported in dogs younger than 3 years and older
than 8 years [34,35].
Figure 3 The distribution of canine L. infantum infection in Europe.
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Clinical manifestations and laboratory
abnormalities
CanL is a systemic disease that may potentially involve any
organ, tissue or body fluid and is manifested by nonspeci-
fic clinical signs. The most common clinical manifesta-
tions and clinicopathological abnormalities found in CanL
are listed in Table 1[2,36,37]. Skin lesions are the most fre-
quent manifestation among them (Figure 5) and may be
seen along with other clinical signs or clinicopathological
abnormalities. However, dogs can be presented with other
clinical signs unrelated to cutaneous lesions as the main
presenting complaint [36,37] (Figure 6). Renal disease may
be the sole clinical manifestation of CanL and it can pro-
gress from mild proteinuria to the nephrotic syndrome or
to an end stage renal disease. Chronic renal failure is a
severe result of disease progression and the main cause of
mortality due to CanL. Despite the high prevalence of
renal pathology in infected dogs [38,39], renal azotemia is
relatively an uncommon laboratory finding. The common
pathological findings detected by cytology (Figure 7) or
histology in CanL [40-43] are listed in Table 2. However,
the variable and nonspecific clinical signs make the list of
differential diagnoses wide and extensive.
Diagnosis
The purposes for which diagnosis of L. infantum infec-
tion is carried out are outlined in Figure 8. Due to these
different diagnostic indications, it is important to
separate Leishmania infection from disease and to apply
different diagnostic techniques for each state. The defi-
nitions of sick versus clinically healthy infected dogs are
shown in Figure 9 [27].
The diagnosis of CanL is complex as the clinical spec-
trum is broad and the range of clinicopathological
abnormalities based on at least a complete blood count
(CBC), biochemical profile and urinalysis can be both
wide and non-specific. A thorough clinicopathological
diagnostic approach needs to be adapted for each
patient when assessing the suspicion of this disease. In
addition, dogs with leishmaniosis might be co-infected
with other vector borne diseases or suffering from other
concomitant infectious or non-infectious diseases mak-
ing the differential diagnoses more complicated and
diverse. Therefore, based on the clinicopathological pro-
blem list, a differential diagnosis and specific diagnostic
approach would be made for each patient.
Different specific diagnostic methods have been
described for the detection of L. infantum infection in
dogs and these are shown in Figure 10. Valid diagnostic
tests are essential for the detection of Leishmania infec-
tion in sick dogs although they lack 100% sensitivity and
specificity [27]. The advantages and disadvantages of the
different diagnostic methods are summarized in Table 3.
The diagnosis of CanL can be made by the detection
of specific serum antibodies (IgG) using preferably
quantitative serological techniques, such as the
Figure 4 Clinical manifestations and immunological characteristics of L. infantum infection in dogs.
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Table 1 Clinical manifestations and laboratory abnormalities found in canine leishmaniosis due to L. infantum
Clinical manifestations Laboratory abnormalities
General
○ Generalized lymphadenomegaly
○ Loss of body weight
○ Decreased or increased appetite
○ Lethargy
○ Mucous membranes pallor
○ Splenomegaly
○ Polyuria and polydypsia
○ Fever
○ Vomiting
○ Diarrhea (including chronic colitis)
Serum proteins and electrophoretogram
○ Hyperglobulinemia
Polyclonal beta and/or gammaglobulinemia
○ Hypoalbuminemia
○ Decreased albumin/globulin ratio
Cutaneous
○ Non-pruritic exfoliative dermatitis with or without alopecia
○ Erosive-ulcerative dermatitis
○ Nodular dermatitis
○ Papular dermatitis
○ Pustular dermatitis
○ Onychogryphosis
CBC/Hemostasis
○ Mild to moderate non-regenerative anemia
○ Leukocytosis or leukopenia
○ Thrombocytopathy
○ Thrombocytopenia
○ Impaired secondary hemostasis and fibrinolysis
Ocular
○ Blepharitis (exfoliative, ulcerative, or nodular) and conjunctivitis (nodular)
○ Keratoconjunctivitis, either common or sicca
○ Anterior uveitis/Endophtalmitis
Biochemical profile/urinalysis
○ Mild to severe proteinuria
○ Renal azotemia
○ Elevated liver enzyme activities
Other
○ Mucocutaneous and mucosal ulcerative or nodular lesions (oral, genital
and nasal)
○ Epistaxis
○ Lameness (erosive or non-erosive polyarthritis, osteomyelitis, polymyositis)
○ Atrophic masticatory myositis
○ Vascular disorders (systemic vasculitis, arterial thromboembolism)
○ Neurological disorders
Figure 5 Different patterns of cutaneous lesions in CanL: A) Exfoliative periocular alopecia and blepharitis; B) Ulcerative nasal
mucocutaneous lesions; C) Papular dermatitis in the inguinal region; D) Nodular crateriform lesions bordering the muzzle; E) Ulcerative
erythematous lesions on the plantar surface of the paw and between pads; F) Onychogryphosis.
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immunofluorescence antibody test (IFAT) and enzyme-
linked immunosorbent assay (ELISA). Immunochroma-
tography-based assays are easy to use and provide rapid
qualitative results on the spot, but their performance is
still not optimal [44-46]. The interpretation of serologi-
cal qualitative rapid tests is described in Figure 11. It is
important to submit samples to a laboratory that runs
quantitative serological assays and can provide an end-
point titer (IFAT) or an optical density reading (ELISA)
and a classification of the level of antibodies [27].
Detection of Leishmania DNA in tissues by PCR
allows sensitive and specific diagnosis of infection. PCR
can be performed on DNA extracted from tissues,
blood, body fluids or even from histopathologic speci-
mens. The different sensitivities of tissues for the detec-
tion of L. infantum by PCR [27,47,48] and variable
sensitivities of PCR techniques are listed in Figure 12.
Assays based on the detection of kinetoplast DNA
(kDNA) appear to be the most sensitive for direct detec-
tion in infected tissues [49,50]. Real-time PCR allows
quantification of the Leishmania parasite load in the tis-
sues of infected dogs, which is useful for the diagnosis
and the follow-up during treatment [51,52]. It is impor-
tant to highlight that information provided by PCR
should not be separated from the data obtained from
clinicopathological and serological evaluations.
A high level of antibodies confirms the diagnosis of
CanL in a dog with clinical signs and/or clinicopatholo-
gical abnormalities compatible with leishmaniosis [53].
However, the presence of a low antibody level is not
necessarily indicative of the disease and further work-up
is necessary to confirm or exclude clinical leishmaniosis
[27]. The diagnostic approach for sick dogs living in an
endemic area is shown in Figure 13. The diagnostic
approach for sick or healthy dogs living in a non-ende-
mic area that have travelled to an endemic area, should
include quantitative serology three months after the
beginning of exposure in the endemic area.
Clinical staging, treatment and prognosis
A system of four clinical stages based on clinical signs,
clinicopathological abnormalities and serological status
was proposed by the LeishVet group in an effort to
cover the wide spectrum of clinical manifestations and
degrees of severity found in CanL [27]. Different treat-
ment protocols and prognoses are suggested for each
clinical stage as described in Table 4.
The most common drugs used for treatment of CanL,
including dosage, combinations and side effects, are
listed in Table 5. Several other candidate medications
against CanL have been studied in vitro or in laboratory
animals but rarely in controlled clinical trials and they
Figure 6 Some clinical signs found in CanL: A) Epistaxis; B) Bilateral uveitis and corneal opacity; C) Purulent conjunctivitis and blepharitis; D)
Exfoliative alopecia in the rear leg and popliteal lymphadenomegaly; E) Marked cachexia and generalized exfoliative alopecia.
Solano-Gallego et al. Parasites & Vectors 2011, 4:86
http://www.parasitesandvectors.com/content/4/1/86
Page 6 of 16
are, therefore, currently not recommended for the rou-
tine treatment of CanL [27].
The clinical response to treatment of sick dogs can
vary from poor to good depending on their overall
initial clinicopathological status and their specific
response to therapy. Dogs with renal insufficiency are
expected to have a lower recovery rate in comparison to
those without kidney compromise or only mild protei-
nuria. Therapy with antileishmanial drugs often leads to
clinical cure [54] although treated dogs may continue to
harbour the parasite and be infectious to sand flies, but
to a lesser extent than pre-treatment [52,55-57].
The vast majority of dogs experience clinical improve-
ment within the first month of therapy [51,52,58]; how-
ever, a longer period of therapy may be required for
others before improvement is apparent. The frequencies
of monitoring and clinicopathological parameters,
including serology, to be followed up during treatment
of CanL are summarized in Table 6.
The length of allopurinol treatment depends on the
severity of the disease, the clinical and parasitological
response to treatment and the individual tolerance to
this drug. Some extremely susceptible dogs never reach
a point that would allow the discontinuation of allopuri-
nol, while others are capable of controlling infection
without the need for extremely lengthy treatment [27].
Allopurinol can be discontinued when the combination
of the following criteria is made:
(1) The presence of complete physical and clinico-
pathological recovery evaluated by a thorough physi-
cal examination, CBC, full biochemistry panel and
urinalysis.
(2) A marked decrease of antibody levels (to negative
or borderline by a quantitative serological assay).
In addition, allopurinol might be discontinued if it is
not possible to control or decrease the xanthinuria with
low purine diets or by reducing the drug’s dosage, to
avoid the risk of urolithiasis, if massive xanthine crystal-
luria is present [59].
Management of clinically healthy infected dogs in
endemic areas
The management of clinically healthy infected dogs in
areas where CanL is endemic is of great importance for
practitioners.
Figure 7 Interpretation of cytology A) Interpretation of cytology
requires time and expertise for the detection of Leishmania
amastigotes when parasites are in low numbers and freed from the
cells. Note the nucleus (N) and the kinetoplast (K) of extracellular
amastigotes (arrows) in a fine needle aspirate of a reactive lymph
node from a dog with clinical leishmaniosis (x100, Diff-quick stain);
B) High numbers of intracellular and extracellular Leishmania
amastigotes in a fine needle aspirate of a reactive lymph node from
a dog with clinical leishmaniosis (x100, modified Giemsa stain).
Table 2 Cytological and histopathological patterns
suggestive of canine L. infantum infection found in
organs or body fluids.
Pathological findings in organs or body fluids
✔ Macrophagic inflammation (granulomatous)
✔ Neutrophilic-macrophagic inflammation (pyogranulomatous)
✔ Lymphoplasmacytic inflammation
✔ Reactive hyperplasia in lymphoid organs
✔ No evidence or variable numbers of intracellular or extracellular
Leishmania amastigotes
Figure 8 The different purposes of CanL diagnosis.
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The presence of Leishmania DNA in the blood or
other tissues of clinically healthy dogs living in endemic
areas indicates that these dogs harbour infection [26],
but they may never develop clinical disease [60]. In con-
trast, a high positive antibody titer may indicate that an
infected dog is heading towards the development of a
widespread infection and future development of clinical
disease [53]. Therefore, we recommend using serology
alone or the combination of serology with PCR for
screening healthy dogs. It is recommended to avoid
screening clinically healthy dogs only by PCR.
Healthy dogs should be screened for Leishmania anti-
bodies as an initial indication for the presence of infec-
tion if [27]:
1. They are scheduled to travel or be exported to
non-endemic areas (Figure 14)
2. They serve as blood donors (Figure 2)
3. Their owners wish to have them monitored at
least every 12 months for early detection of infection
and the potential to develop disease.
PCR should be used for the second above indication
and as an ancillary test for the first and third above
indications.
The management of a clinically healthy seropositive
dog and a clinically healthy seronegative and PCR-posi-
tive dog is summarized in Figure 14.
Prevention
Current preventative measures are mainly based on the
use of veterinary registered products containing syn-
thetic pyrethroids, permethrin, or deltamethrin with a
repellent effect against sand flies whose efficacy has
been demonstrated both experimentally [61-63] and in
field studies [64-68]. These products are available in
spot on formulation or in a collar form and they
reduce the risk of new infections and the biting of
sand flies on already infected dogs [64-68]. Other mea-
sures useful in the prevention of sand fly bites include
[69,70]: 1) keeping the dog indoors during the sand fly
season from dusk to dawn; 2) reducing microhabitats
favourable to sand flies such as piles of wood and
Figure 9 Definition of L. infantum-infected but healthy versus sick dogs. Dogs with clinical leishmaniosis are defined as those presenting
clinical signs and/or clinicopathological abnormalities and having a confirmed L. infantum infection. Dogs with subclinical infection, or clinically
healthy but infected dogs, are defined as those that present neither clinical signs on physical examination nor clinicopathological abnormalities
by routine laboratory tests (CBC, biochemical profile and urinalysis) but have a confirmed L. infantum infection.
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stones in the vicinity of the house and in other loca-
tions where dogs spend time; 3) usage of indoor insec-
ticide treatment [27].
Long-acting topical insecticides evaluated in several
published field studies [64-68] should be applied to dogs
living or travelling to endemic areas as follows:
- Permethrin/Imidacloprid spot on formulation:
Treatment provides repellent (anti feeding) activity
against sand flies (P. perniciosus) for three weeks
[61]. Repeat administration every 3 weeks. It should
be applied at least 2 days before travelling
- Deltamethrin collars: Control of feeding by phlebo-
tomine sand flies (P. perniciosus) for a period of 5-6
months [63]. Replace collar every 5-6 months. It
should be applied at least 1-2 weeks before travelling.
Veterinarians and dog owners are advised to carefully
check the product’s label recommendations and follow
the manufacturer’s instructions for the correct applica-
tion and frequency of reapplication. Client education on
the maintenance of an appropriate insecticide [27]
throughout the period of sand fly activity in the Medi-
terranean basin (April-November) is also crucial for the
protection of dogs [71].
Purified Leishmania fraction vaccines appear currently
to be the most effective and promising vaccines for
dogs. These include the ‘’fucose mannose ligand’’
(FML)-based vaccine [72,73] and an excreted/secreted
antigen purified from specific-medium culture superna-
tant of L. infantum based vaccine [74]. The FML-based
vaccine is currently available commercially in Brazil.
The same vaccine has also been proposed as a transmis-
sion-blocking vaccine [75]. Recently, another vaccine
which contains the recombinant A2 protein and saponin
as adjuvant has also been approved in Brazil [76]. In
Europe, a different vaccine based on cultured L. infan-
tum purified excreted/secreted antigens has been
approved for vaccination of dogs [74].
The future for CanL control should be an integrated
approach to prevention including vaccination against L.
infantum with an effective canine vaccine and the use of
long-acting topical insecticide applications. A vaccine
would prevent the establishment of infection introduced
Figure 10 The most common diagnostic methods for CanL.
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by the bites of those sand flies that escape the insecticide
effect [50].
Public health considerations
In Southern Europe, human visceral leishmaniosis
caused by L. infantum is a zoonotic disease that affects
young children or adults suffering from the Acquired
Immune Deficiency Syndrome (AIDS) or immunosup-
pressive conditions [77,78]. Dogs are considered the
most important peridomestic reservoir of L. infantum
infection for humans. However, the ownership of an
infected dog does not appear to greatly increase the risk
Table 3 Advantages and disadvantages of common diagnostic methods for the detection of L. infantum infection in
dogs
DIAGNOSTIC
TECHNIQUES
ADVANTAGES DISADVANTAGES
SEROLOGY • Determination of antibody level which is essential for the
diagnosis and establishing a prognosis
• Does not detect the actual presence of the Leishmania
parasite
• Serocrossreactions with trypanosomes
QUALITATIVE • Rapid in-clinic test • Provides only positive or negative result
• Variable sensitivities and performance with risk of false
negatives
• A positive result needs to be further evaluated by a
quantitative serology
QUANTITATIVE
(IFAT, ELISA)
Determines the antibody level
• High antibodies levels in the presence of compatible clinical
signs and/or clinicopathological abnormalities are conclusive
of clinical leishmaniosis
• Performance and accuracy of cut-off will depend on the
laboratory
• Differences between laboratories and poor standardization of
techniques
• Low antibody levels will require further work-up
CYTOLOGY/
HISTOPATHOLOGY
Permits direct detection of the parasite itself and the type of
pathological findings:
- Pathological findings suspicious of infection
- Allows exclusion of other differential diagnoses
- Rapid and non invasive (cytology)
• Low sensitivity for the detection of Leishmania amastigotes in
tissues or body fluids
• Requires the performance of other diagnostic tests such as
immunohistochemistry and/or PCR when parasites are not
visualized
• Does not reveal the immunological status of the dog
• Needs expertise
PCR • Allows the detection of leishmanial DNA
• High sensitivity (kDNA) and specificity
• Parasitic load quantification (if Real time-PCR)
• False positive results possible due to DNA contamination
• Different standardization and techniques used by different
diagnostic laboratories
• Does not reveal immunological status
• It cannot be performed as the sole diagnostic technique for
the confirmation of the disease because a positive result
confirms Leishmania infection but not disease
PARASITE
CULTURE
• Permits the isolation of Leishmania parasites
• Facilitates the isoenzymatic identification of the parasite
• Time-consuming and laborious diagnostic technique
• It can require one month to provide a result
• Performed only in research laboratories
Figure 11 Interpretation of serological qualitative rapid tests for CanL.
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Figure 12 Selection of tissues to be used for PCR and types of PCR techniques when suspecting CanL.
Figure 13 Flow chart for the diagnostic approach to dogs with suspected clinical signs and/or clinicopathological abnormalities
consistent with CanL.
Solano-Gallego et al. Parasites & Vectors 2011, 4:86
http://www.parasitesandvectors.com/content/4/1/86
Page 11 of 16
of disease in the family when transmission is already
present in the region [50].
Conclusions
The complexity of CanL and the wide range of its clini-
cal manifestations, from inapparent infection to severe
disease, make the management of CanL challenging.
Diagnosis is performed based on clinicopathological
manifestations and by confirmation of infection using
mainly serological and molecular techniques. A staging
system that divides the disease into four stages is aimed
at assisting the clinician in determining the appropriate
therapy, forecasting prognosis, and implementing fol-
low-up steps required for the management of the leish-
maniosis patient. Prevention should be an integrated
approach including vaccination against L. infantum with
Table 4 Clinical staging of canine leishmaniosis based on serological status, clinical signs, laboratory findings, and
type of therapy and prognosis for each stage [27]
Clinical
stages
Serology * Clinical signs Laboratory findings Therapy Prognosis
Stage I
Mild
disease
Negative to
low positive
antibody
levels
Dogs with mild clinical signs such
as peripheral lymphadenomegaly,
or papular dermatitis
Usually no clinicopathological
abnormalities observed
Normal renal profile: creatinine <
1.4 mg/dl; non-proteinuric:
UPC < 0.5
Scientific neglect/allopurinol or
meglumine antimoniate or
miltefosine/allopurinol +
meglumine antimoniate or
allopurinol + miltefosine**
Good
Stage II
Moderate
disease
Low to high
positive
antibody
levels
Dogs, which apart from the signs
listed in stage I, may present:
diffuse or symmetrical cutaneous
lesions such as exfoliative
dermatitis/onychogryphosis,
ulcerations (planum nasale,
footpads, bony prominences,
mucocutaneous junctions),
anorexia, weight loss, fever, and
epistaxis
Clinicopathological abnormalities
such as mild non-regenerative
anemia, hyperglobulinemia,
hypoalbuminemia, serum
hyperviscosity syndrome
Substages
a) Normal renal profile:
creatinine < 1.4 mg/dl; non-
proteinuric: UPC < 0.5
b) Creatinine <1.4 mg/dl;
UPC = 0.5-1
Allopurinol + meglumine
antimoniate or allopurinol+
miltefosine
Good to
guarded
Stage III
Severe
disease
Medium to
high positive
antibody
levels
Dogs, which apart from the signs
listed in stages I and II, may
present signs originating from
immune-complex lesions: vasculitis,
arthritis, uveitis and
glomerulonephritis.
Clinicopathological abnormalities
listed in stage II
Chronic kidney disease (CKD) IRIS
stage I with UPC > 1 or stage II
(creatinine 1.4-2 mg/dl) [79]
Allopurinol + meglumine
antimoniate or allopurinol +
miltefosine
Follow IRIS guidelines for CKD
[80]
Guarded
to poor
Stage IV
Very
severe
disease
Medium to
high positive
antibody
levels
Dogs with clinical signs listed in
stage III. Pulmonary
thromboembolism, or nephrotic
syndrome and end stage renal
disease
Clinicopathological abnormalities
listed in stage II
CKD IRIS stage III (creatinine 2-5
mg/dl) and stage IV (creatinine >
5 mg/dl) [79] Nephrotic
syndrome: marked proteinuria
UPC > 5
Allopurinol (alone)
Follow IRIS guidelines for CKD
[80]
Poor
*Dogs with negative to medium positive antibody levels should be confirmed as infected by other diagnostic techniques such as cytology, histology,
immunohistochemistry or PCR. High levels of antibodies, defined as a 3-4 fold elevation above the cut off level of a well established reference laboratory, are
conclusive of a diagnosis of CanL. **Dogs in stage I (mild disease) are likely to require less prolonged treatment with one or two combined drugs or alternatively
monitoring with no treatment. However, there is limited information on dogs in this stage and, therefore, treatment options remain to be defined.
Table 5 Current treatment protocols for canine leishmaniosis [27]
Drugs Dosages Main side effects References
Meglumine antimoniate* 75-100 mg/kg once a day or 40-75 mg/kg twice a day for 4 weeks, S.C.** Potential nephrotoxicity
Cutaneous abscesses/cellulitis
[52,55,57,81-83]
Miltefosine* 2 mg/kg/once a day for 28 days P.O. Vomiting Diarrhea [83-85]
Allopurinol 10 mg/kg twice a day for at least 6-12 months P.O. Xanthine urolithiasis [51,59,86-89]
*Registered for veterinary use in most European countries; both drugs are commonly recommended in combination with allopurinol.
P.O.: per os; S.C.: subcutaneous
**Treatment prolongation by 2-3 weeks may be considered if patient improvement is insufficient.
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an effective canine vaccine and the application of a topi-
cal insecticide.
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Deoxyribonucleic acid; ELISA: Enzyme-linked immunosorbent assay; FML:
Fucose mannose ligand; IFAT: Immunofluorescence antibody test; IgG:
Immunoglobulin G; IRIS: International Renal Interest Society; kDNA:
Kinetoplast DNA; MHC II: Major histocompatibility complex type II; N-RAMPI:
Natural Resistance-associated Macrophage Protein one; PCR: Polymerase
chain reaction; P.O.: per os; S.C.: subcutaneous; Slc11c1: Solute carrier family
11 member a1; UPC: Urinary protein creatinine ratio; USA: United States of
America
Figure 14 Management of Leishmania-seropositive but clinically healthy dogs and PCR-positive but seronegative dogs. Clinically
healthy but seropositive dogs would normally present with low antibody titers and should be confirmed by retesting. Confirmed seropositive
dogs should be monitored with physical examinations, routine laboratory tests and serological tests on a regular basis every 3-6 months to
assess the progression of infection towards disease.
Table 6 Treatment of canine leishmaniosis - recommended monitoring of clinicopathological parameters and serology
including frequency of follow up [27]
Parameters Frequency
Clinical history and complete physical examination
Routine laboratory tests:
Complete CBC, biochemical profile, serum electrophoresis
(optional) and complete urinalysis including UPC in proteinuric dogs.
After the first month of treatment and then every 3-4 months during the first
year. Later on, if the dog is fully recovered clinically with treatment, a recheck
would be recommended every 6 months or once a year.
Serology* Not before 6 months after initial treatment and every 6 months or once a
year thereafter.
Real time PCR Can optionally be carried out at the same time as serology. The full
usefulness of this assay for follow up during treatment is currently
undetermined.
*Some dogs present a significant decrease in antibody levels (more than a two-fold dilutions difference between the first and the following samples) associated
with clinical improvement within 6 months to 1 year of treatment. Other dogs might not have a decrease in antibody levels despite clinical improvement. In
contrast, a marked increase of antibody levels (more than two-fold elevation between monitoring samples) should be interpreted as a marker of relapse,
especially in dogs following the discontinuation of treatment [27].
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